Literature DB >> 10503801

Worst-rank score analysis with informatively missing observations in clinical trials.

J M Lachin1.   

Abstract

Many randomized clinical trials schedule subjects to undergo some assessment at a fixed time (or times) after the initiation of treatment. Often, these follow-up measurements may be missing for some subjects because a disease-related event occurred prior to the time of the follow-up observation. For example, a study of congestive heart failure may schedule patients to undergo exercise testing at 12 weeks, but this measurement may be missing for those who died of heart disease during the study. In such cases, the measurements are informatively missing because mortality from heart disease and a decline in exercise both indicate progression of the underlying disease. It is inappropriate, therefore, to treat these missing observations as missing-at-random and ignore them in the analysis. In one approach to this problem, investigators have included such patients in the analysis of the follow-up data by assigning a rank that represents a "worst-rank score" relative to those actually observed. Some, however, have criticized this procedure as having the potential to produce biased results. In this paper, we explore the statistical properties of such an analysis. We show under a specific model that the imputation of a worst-rank score for informatively missing observations provides an unbiased test against a restricted alternative. We also describe generalizations that employ the actual times of the informative event. We present an example from a study of congestive heart failure. Last, we discuss the implications of this approach and of other methods.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10503801     DOI: 10.1016/s0197-2456(99)00022-7

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  47 in total

1.  Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations.

Authors:  Roland A Matsouaka; Rebecca A Betensky
Journal:  Stat Med       Date:  2014-11-13       Impact factor: 2.373

2.  Prenatal Repair of Myelomeningocele and School-age Functional Outcomes.

Authors:  Amy J Houtrow; Elizabeth A Thom; Jack M Fletcher; Pamela K Burrows; N Scott Adzick; Nina H Thomas; John W Brock; Timothy Cooper; Hanmin Lee; Larissa Bilaniuk; Orit A Glenn; Sumit Pruthi; Cora MacPherson; Diana L Farmer; Mark P Johnson; Lori J Howell; Nalin Gupta; William O Walker
Journal:  Pediatrics       Date:  2020-02       Impact factor: 7.124

3.  Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs.

Authors:  Karl V Clemons; Gloria M Gonzalez; Gaurav Singh; Jackie Imai; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

4.  Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.

Authors:  Javed Butler; Kevin J Anstrom; G Michael Felker; Michael M Givertz; Andreas P Kalogeropoulos; Marvin A Konstam; Douglas L Mann; Kenneth B Margulies; Steven E McNulty; Robert J Mentz; Margaret M Redfield; W H Wilson Tang; David J Whellan; Monica Shah; Patrice Desvigne-Nickens; Adrian F Hernandez; Eugene Braunwald
Journal:  JAMA Cardiol       Date:  2017-09-01       Impact factor: 14.676

6.  An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.

Authors:  Roland A Matsouaka; Aneesh B Singhal; Rebecca A Betensky
Journal:  Stat Methods Med Res       Date:  2016-12-29       Impact factor: 3.021

7.  Experimental evidence that granulocyte transfusions are efficacious in treatment of neutropenic hosts with pulmonary aspergillosis.

Authors:  Marife Martinez; Vicky Chen; Ann-Jay Tong; Kelsey Hamilton; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

8.  Efficacy of posaconazole in a murine model of central nervous system aspergillosis.

Authors:  Jackie K Imai; Gaurav Singh; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Effect of aerobic exercise and relaxation training on fatigue and physical performance of cancer patients after surgery. A randomised controlled trial.

Authors:  Fernando C Dimeo; Frank Thomas; Cornelia Raabe-Menssen; Felix Pröpper; Michael Mathias
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

10.  Predictors of 6-month health utility outcomes in survivors of acute respiratory distress syndrome.

Authors:  Samuel M Brown; Emily Wilson; Angela P Presson; Chong Zhang; Victor D Dinglas; Tom Greene; Ramona O Hopkins; Dale M Needham
Journal:  Thorax       Date:  2016-07-20       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.